8-9 MAY 2024
DUBAI WORLD TRADE CENTRE
The future of healthcare is targeted, and it is precise!
As the premier exhibition and conference dedicated to precision medicine and personalised healthcare in the Middle East, PrecisionMed Exhibition & Summit (PMES) serves as a vital platform for advancing knowledge and embracing pertinent solutions. Now entering its third year, this event will unite more than 7,000 healthcare professionals, including clinicians, disease specialists, hospital and laboratory management, research centers, pharma and bio-pharma company representatives, dealers and distributors, public sector policymakers, health tech innovators, and investors, for a two-day exhibition and conference at the esteemed Dubai World Trade Centre in May 2024.
The 2024 conference is a CME accredited event allowing healthcare professionals to collect credits to count towards their ongoing education. The number of credits awarded will be available closer to the time of the conference. The conference will feature pioneering scientific insights on precision medicine, presented by respected speakers from both the MENA region and from around the globe.
In 2024, our focus will center on four key pillars: Healthy Populations, Lifestyle Intervention and Disease Prevention, Clinical Genomics, and AI in Precision Medicine, all with the shared goal of expediting the clinical integration of precision medicine for the betterment of the broader patient community.
PrecisionMed Exhibition & Summit is running concurrently with the EMERGE 2050 investment forum, a thriving hub for pioneering health-tech startups to connect with potential investors.
Top 5 Reasons Why this is a “Must Attend” Event
• Explore the latest products and services, gaining exposure to emerging technologies that can contribute to advancements in personalised healthcare.
• Attend presentations by knowledge and thought leaders and gain first-hand knowledge about the latest advancements and breakthroughs in precision medicine. Leading experts and researchers share their insights into genomics, biomarker discovery, and personalized therapeutics, providing attendees with a comprehensive understanding of the current state and future directions in precision medicine especially in the MENA region.
• Engage with stakeholders and partners through the networking app, weeks before doors open. Shorten discussion timelines. Arrange to meet at the show.
• Access to EMERGE 2050, an event that brings together life science investors and health-tech disruptors in a unique conference, exhibition and meet and match setting. Emerge 2050 is dedicated to industry digitisation, cost savings and efficiency in healthcare.
• PrecisionMed Exhibition & Summit is CME accredited. Earn Credits for ongoing career development requirements.
Pillars
Healthy Populations Clinical Genomics
Healthy Populations
Lifestyle Intervention and Disease Prevention
AI in Precision Medicine
The theme “Healthy Populations” will delve into the genomic landscape of the MENA region, encompassing discussions on government regulations, burgeoning national genome initiatives, and the swift implementation of genome sequencing for critically ill newborns. A distinguished keynote speaker of international acclaim will provide a comprehensive global perspective, paving the way for subsequent presentations and panel discussions featuring experts from the region.
Lifestyle Intervention and Disease Prevention
Lifestyle Intervention and Disease Prevention will explore the scientific underpinnings of disease prevention through lifestyle modifications, the utilisation of data access to bolster large-scale disease prevention efforts, and the potential financial benefits for both insurers and patients stemming from disease prevention. The event will showcase findings from international and local studies, accompanied by panel discussions focused on charting the future course of action.
Clincial Genomics
This theme will highlight the rapid advancements in precision medicine fuelled by recent scientific breakthroughs. The theme will feature insights from leading experts in genomic clinical trials, with a focus on rare diseases, immunotherapy, oncology and upcoming developments in pharmaceuticals. Additionally, attendees will gain an understanding of the accelerating impact of multi-omics on expediting screening for quicker diagnosis and application of precision medicine in the hospital setting.
Dr. Min S. Park
Chief Scientific Officer, Sanimed International
Patrick Merel. PhD
Genomics and Molecular Biotech Sr Director, Technical Innovation Institute (TII)
Dr. Khalid Fakhro
Chief Research Officer, Sidra Medicine
Dr. Julie Decock
Scientist, Qatar Biomedical Research Institute
Prof. George P. Patrinos
Professor and Head of Laboratory; Editor-in-Chief, The Pharmacogenomics Journal, University of Patras
Dr. Ahmad Abou Tayoun
Director, Al Jalila Children’s Genomics Center of Excellence; Associate Professor of Genetics, MBRU
Dr. Shaikha AlMazrouei
Lead Researcher, Technical Innovation Institute (TII)
Prof. Fatma Al Jasmi
Chair of Genetics & Genomics Department, UAE University College of Medicine & Health Science
Mohamed Nagy
Head of Personalised Medication Management Unit, Children’s Cancer Hospital, Egypt
Prof. Bassam Ali
Professor in Molecular and Genetic Medicine & Leader of the Genetics and Development Research, UAE University
Dr. Khulood Alsayegh, MD
Head of Clinical Standards and Guidelines, Dubai Health Authority
Dr. Wejdan M. Alenezi
Personalized Healthcare NEOM
Dr. Halima Bensmail
Principal Scientist Qatar Computing Research Institute; Professor, HBKU; Member of the Advisory Board of International AIQT
Co-director of the Program in Medical & Population Genetics, Broad Institute; Chief Genomics Officer, Department of Medicine, Massachusetts General Hospital (MGH); Professor of Pathology, Harvard Medical School
Nader Al-Dewik, PhD
Director of Translational and Precision Medicine Research, Principal Investigator, Hamad Medical Corporation (HMC)
Albarah Elkhani
Senior Vice President - Operations M42
Almaghlouth
Director, Population Health Activation Program NEOM
Dr. Stephen R. Grobmyer, MD
Chair of the Oncology Institute, Cleveland Clinic Abu Dhabi
Dr. Maxime Hebrard
Senior Scientist, A*STAR – Genome Institute of Singapore
Prof. Faisal Alsaif Director of Health Planning, NEOM
Dr. Ozge Ceyhan Birsoy
Associate Director, Memorial Sloan Kettering Cancer Center, Diagnostic Molecular Genetics Laboratory
Ammira Al-Shabeeb Akil, PhD
Head of Genetic and Metabolic Clinical research program; Principal Investigator, Precision Medicine of Diabetes Prevention Lab, Sidra Medicine
Momchilo Vuyisich
Co-founder, Chief Science Officer, and Head of Clinical Research, Viome Life Sciences
Ibrahim
Dr. Hazim Najjar, MD, ABMGG, FACMG Executive Board Member, Saudi Society of Medical Genetics
Program Lead, Hereditary High Risk and Cancer Survivorship Programs, Oncology Institute, Cleveland Clinic Abu Dhabi
Dr. Alessio Squassina
Associate professor of Pharmacology; Chief – Laboratory of Pharmacogenomics, Dept of Biomedical Sciences, University of Cagliari
Dr. Georgios Pavlou Founder, VNous
Dr. Maria Vranceanu
Researcher, University of Medicine and Pharmacy Cluj Napoca, Romania
Co-Founder, CEO at Pragma Bio
Shruti Sinha, PhD
Bioinformatics Scientist, Al Jalila Children’s Specialty Hospital
of Scientific Market Development, Olink Proteomics
Dr. Ali Tinazli Chief Executive Officer, lifespin GmbH
Dr. Fawad Khan
Sharmeen Roy, PharmD, BCPS Chief Strategy & Science Officer, DoseMeRx
Dr. Reham Kotb
Assistant Prof. of Public Health, Chair of the Environmental and Public Health Department College of Health Sciences, Abu Dhabi University
Mohammed Uddin, Ph.D
Director, Center for Applied and Translational Genomics (CATG), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health
Radhakrishnan Mahalingam
Healthcare Transformation Leader
Dr. Chiara Cugno
Director of Advanced Cell Therapy Core; Attending Physician, Sidra Medicine
Moeen Riaz Principal Scientist, Regeneron Genetics Center
Dr. Tomader Ali
Clinical Research and Trials Project Lead + HCP (Diabetes Education) Faculty, Imperial College London Diabetes Centre
Mohamed Alameri, PhD, AFHEA
Head of Section, Department of Health, Abu Dhabi
M. Walid Qoronfleh, Ph.D., MBA
Executive Director, Q3 Research Institute (QRI)
Mr. Jimi Olaghere
CRISPR Gene Editing Recipient
Alexandre Guenoun
Founder & CEO, Kiro
CONFERENCE AGENDA DAY 1. 08 MAY 2024
am
pm
Opening Ceremony
Introduction
Welcome From PMES
Opening Address Presentation
Rachel McArthur, MENA Healthcare Journalist, Digital Ink Media
Keynote Adress
Importance of personalised healthcare to address national healthcare challenges in the Gulf
CRISPR Gene editing success story: Personal patient success story of Jimi of an experimental gene editing treatment to treat sickle cell disease
Dubai Digital Strategy
Coffee Break and Exhibition Tour with Dignitaries
Session 1: Healthcare structures and its impact on Public Health
Presentation
Presentation
pm Registration
Session 3: Population Genome Sequencing MENA Region Presentation Presentation Panel Session Welcome Note
Current structures of healthcare to include precision medicine and it's impact on public health
Impacts of the new UAE genome law
Session 2: Population Genome Sequencing Global Presentation Presentation Presentation Presentation
All of Us and the US genomic screening project and how to implement the data into a clinical practice in aid of the patient.
World Health Organisation (WHO) genomics program for equitable global implementation of human genomics
Singapore National Precision Medicine Program
Path to Precision Medicine: From millions of exomes to clinical development
The implementation of Precision Medicine in North Africa
UAE's Journey from Population Genomics to Precision Medicine
MENA Genome Program
Moderated by: Albarah Elkhani, Senior Director, Operations, M42
Dr. Min S. Park Scientific Committee Chairman
DHA
Jimi Olaghere
CRISPR Gene Editing recipient
Dr. Khulood Alsayegh, MD
Head of Clinical Standards and Guidelines, Dubai Health Authority
Dr. Reham Kotb, Assistant Professor of Public Health, Health Sciences, College of Health Science, Abu Dhabi University
Andrea Tithecott, Partner, Head of Regulatory Practice, Al Tamimi & Company
Heidi Rehm, Co-director of the Program in Medical and Population Genetics, Broad Institute; Chief Genomics Officer, Department of Medicine, Massachusetts General Hospital (MGH); Professor of Pathology, Harvard Medical School
Dr. Ahmad Abou Tayoun, Director, Al Jalila Children’s Genomics Center of Excellence; Associate Professor of Genetics, Mohammad Bin Rashid University
Dr. Maxime Hebrard Ph.D., Genome Institute of Singapore
Dr. Moeen Riaz
Principal Scientist/Manager at Founder and Special populations group at Regeneron Genetics Center (RGC), Regeneron Pharmaceuticals Inc, New York USA
Dr. Yosr Hamdi, Pasteur Institute de Tunisia
Albarah Elkhani
Senior Director, Operations, M42
• Dr Mohammed Alameri, Section Head Studies and Special Projects, DOH, Abu Dhabi
• Dr. Wejdan M. Alenezi, Personalized Healthcare, NEOM
• Dr. Said Ismail, PhD, Qatar Genome Director, Qatar Foundation
• Dr. Stephen R. Grobmyer, MD, Chair of the Oncology Institute, Cleveland Clinic Abu Dhabi
• Dr Ghada El-Kamah, Professor of Clinical Genetics, Coordinator of the Hereditary Bloders and Genodermatoses Clinics and Research Team, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
4: Inherited Diseases
Emirati Hereditary High Risk Program
Translating long reads in the clinic
5: New Born Screening
Precision Medicine Activities and Opportunities for Shaping Maternal and Neonatal Health in Qatar
Innovative Strategies for Human Rare Pediatric Hereditary Diseases
Precision rapid (Point-of-Care) Genetic testing to prevent irreversible Hearing Loss in New Borns receiving Aminoglycosides antibiotics
Lifestyle Intervention and Disease Prevention
Population health management
Regenarative Organ on chip - vascular models for brain diseases
Topic name to be shared
Next-Generation Precision Medicine Towards Patient Centricity and Precision Wellness – Are we ready?
Unlocking HealthSpan and Longevity: Lifestyle Interventions and Precision Health
Dr. Fawad Khan, Department Chairman - Primary Care, Program LeadHereditary High Risk and Cancer Survivorship Programs, Precision Medicine, Cleveland Clinic, Abu Dhabi
Dr. Ahmad Abou Tayoun, Director, Al Jalila Children’s Genomics Center of Excellence; Associate Professor of Genetics, Mohammad Bin Rashid University
Dr. Nader Al-Dewik, PhD Director of Translational and Precision Medicine Research, Principal Investigator, HMC
Dr. Sahar Da'as, Research Manager, Sidra Medicine and Assistant Professor, College of Health & Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar
Dr. Hazim Najjar, MD, ABMGG, FACMG Molecular Genetics & Clinical Pathology Board Member, Saudi Society of Medical Genetics
Ibrahim Almaghlouth, Director of Population Health Activation Program, NEOM
Georgios Pavlou, PhD, Founder - Vnous
Gruppo San Donato
M. Walid Qoronfleh, Ph.D., MBA, Executive Director of the US-based Q3 Research Institute (QRI)
Dr. Anmol Kapoor Cardiologist, CEO and Founder, BioAro Inc.
The future of personalized nutrition: nutrigenomics and gut microbiome
Nutrigenomics and treatment through diet-gene interaction as a complementary therapy in cancer prevention and treatment
Translating Lifestyle: From Mice to Men - Insights into overweight, Diets, and Health through Translational Imaging and Precision Medicine
Data-driven and AI-computed personalized nutrition for preventive medicine
Dr. Farah Hillou, Wellbeing Counselor, M42
Dr. Maria Vranceanu, CEO, Eva Precision Nutrition , Project Coordinator, University of Medicine and Pharmacy Cluj Napoca, Romania
Dr. Zani Michele, Global Sales Director Clinical , Bruker BioSpin
CONFERENCE AGENDA DAY 2. 09 MAY 2024
Abu Dhabi’s vision on the growth and scientific breakthroughs in clinical genomics & application
Implementing Precision Medicine (PM) for better health care for rare disorders
Session 1: AI in Precision Medicine Keynote Keynote Panel Discussion Coffee Break and Networking
Session 2 : Hematology Presentation
AI and tech advancements
Ethics / Regulation of Ai in Healthcare
AI the backbone of Precision Medine and how regulations can keep up with the ever changing technology
Chaired by: Thomas Launey, Chief Researcher, Technical Innovation Institute (TII)
Dr. Shahrukh Hashmi, Department of Health – Abu Dhabi (DoH)
Ghada El-Kamah MBBCh, MSc, PhD
Professor of Clinical Genetics, coordinator of The Hereditary Blood Disorders (HBD) and Genodermatoses clinics and research team, Human Genetics and Genome Research Institute (HGGRI), National Research Centre (NRC), Cairo
Dr. Halima Bensmail, Principal Scientist Qatar Computing Research Institute; Professor, HBKU; Member of the Advisory Board of International AIQT
Dr. Khulood Alsayegh, MD
Head of Clinical Standards and Guidelines, Dubai Health Authority
• Dr. Khulood Alsayegh, MD, Head of Clinical Standards and Guidelines, Dubai Health Authority
• Dr. Zara Ghazoui, PhD, Director of Data Strategy and AI , AstraZeneca
• Dr Anne Mottram, NEOM
• Hany Elosman, Director of technology of AI, NEOM
Unlocking the full potential of precision oncology through rapid molecular profiling
Precision Medicine approaches in Hematology
Session 3: Advancement of diabetes genomic research in the region Presentation Presentation Presentation Panel Discussion
DIA-MENA: Type 1 Diabetes Islet Autoantibody Screening Program in the MENA: a Pilot-Cross Sectional prospective cohort study
Molecular and cellular pathways links clinical guidelines and therapies that are highly specific and efficacious.
Groundbreaking Science in Diabetes –Transforming Patient Pathways
Advancement of diabetes genomic research in the region
Dr. Philip Jermann
Medical Affairs Director at Thermo Fisher Scientific
Panel session by Thermo Fisher Scientific
Ammira Al-Shabeeb Akil, PhD, Head of Genetic and Metabolic clinical research program; Principal Investigator, Precision Medicine of Diabetes Prevention Lab, Sidra Medicine
Tomader Ali, Imperial College London Diabetes Centre (ICLDC)
Shaun David Randles, Pharma Team Leader, Randox
• Ammira Al-Shabeeb Akil, PhD
• Tomader Ali
• Shaun David Randles
Session 4: Decoding Hereditary Cancer Risks, Oncology and Autoimmune Pathological Applications
Lessons learned from expanded genetic testing of a broad cancer patient cohort using paired tumor-normal sequencing
Exploring the Horizon: Liquid Biopsy and droplet digital PCR improving precision and accuracy.
Precision Oncology: Leveraging Genomics for Personalized Cancer Care
Investigating the Versatility and Clinical Significance of Oncological and Autoimmune Pathological Applications in Modern Medicine
Chaired by: Dr. Shaikha AlMazrouei, Lead Researcher, TII
Dr. Ozge Birsoy
Associate Director, Diagnostic Molecular Genetics, Associate Professor/Member of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
Dr. Marco Bianchi
Bio-Rad Laboratories
Suruchi Aggarwal, Ph.D.
Head - Scientific Affairs, MedGenome
Dr. Shahrukh Hashmi, DoH – Abu Dhabi Other panel members TBA